A Rare Case Report on Ewing’s Sarcoma and Its Clinical Management: A Role of Clinical Pharmacist’s Intervention for Achieving Better Therapeutic Outcome in Cancer Care

Abstract

Ewing’s sarcoma is a highly malignant tumor of bone that occurs in children’s, adolescents, and young adults. Ewing’s sarcoma has an extremely high fatality rate. The main objective of this study was to spread awareness to the healthcare professionals regarding rare clinical condition, drug related problems with preventive measures and clinical management of rare disease. The main clinical pharmacist intervention made after reviewing the patient case profile clinical pharmacist has suggested a preventive measures and clinical management of drug related problems to medical oncology for better therapeutic outcome in cancer care, so patient health related quality of life will be improve. The following drug related problems and clinical managements are mentioned in below. Clinical pharmacist has monitored and reported ifosfamide induced hematuria and suggested to prescribe Injection Mesna 200 mg at 0-4-8 hourly for prevention of ifosfamide related bladder toxicity. Clinical pharmacist after reviewing of all previous CBC results and suggested to medical oncologist to prescribe Injection Pegfilgrastin 300 mcg SC (1 day) instead of Injection Filgrastine 300 mcg SC (4 days). Pegfilgrastin has a better efficacy, potency and reduced the prolongation of hospital related cost because of reduction of frequency of treatment drug. We have described a unique case of Ewing’s sarcoma and its clinical management so many healthcare professional will get critical information related to rare type of cases. In this case role of clinical Pharmacist's interventions is most important for achieving better therapeutic outcomes and patient health related quality of life and cost in cancer care as well as reduced the burden of the medical oncologist.